Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment

MLA

William S. Weintraub, et al. “Cost-Effectiveness of Icosapent Ethyl for High-Risk Patients With Hypertriglyceridemia Despite Statin Treatment.” JAMA Network Open, vol. 5, no. 2, Feb. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a0c10599e0d53a2e87f4105d23b2e3f2&authtype=sso&custid=ns315887.

APA

William S. Weintraub, Deepak L. Bhatt, Zugui Zhang, Sarahfaye Dolman, William E. Boden, Adam P. Bress, Jordan B. King, Brandon K. Bellows, Gabriel S. Tajeu, Catherine G. Derington, Jonathan Johnson, Katherine Andrade, P. Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Jean-Claude Tardif, Christie M. Ballantyne, & Paul Kolm. (2022). Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Network Open, 5(2).

Chicago

William S. Weintraub, Deepak L. Bhatt, Zugui Zhang, Sarahfaye Dolman, William E. Boden, Adam P. Bress, Jordan B. King, et al. 2022. “Cost-Effectiveness of Icosapent Ethyl for High-Risk Patients With Hypertriglyceridemia Despite Statin Treatment.” JAMA Network Open 5 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a0c10599e0d53a2e87f4105d23b2e3f2&authtype=sso&custid=ns315887.